Adrenomed AG Seeks Patent for Method of Modulating the Activity of Adrenomedullin in a Subject in Need of Therapeutic Intervention for Organ Dysfunction or Organ Failure Associated with Adrenomedullin (ADM) Activity by Administering an Anti-Adrenomedullin (ADM) Antibody or an Anti-ADM Fragment to the Subject

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Global IP News (India), March 29, 2019 Pharmaceutical Patent News, 3pp
  • Additional Information
    • Abstract:
      Alexandria, March 29 -- Adrenomed AG has sought a patent for method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adrenomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM fragment to the subject. Bergmann Andreas developed the invention...